Associated Papers
Proteomic analysis reveals dual requirement for Grb2 and PLCγ1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation.
Peiris MN et al.
Oncotarget, 2022
Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome.
Chong Y et al.
International Journal of Cancer, 2020
Breakpoint Cluster Region-Mediated Inflammation Is Dependent on Casein Kinase II.
Meng J et al.
Journal of Immunology (baltimore, Md. : 1950), 2016
BCR: a new target in resistance mediated by BCR/ABL-315I?
Haberbosch I et al.
Genes & Cancer, 2016
Regulation of dendritic arborization by BCR Rac1 GTPase-activating protein, a substrate of PTPRT.
Park AR et al.
Journal of Cell Science, 2012
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.
Medves S et al.
Journal of Cellular and Molecular Medicine, 2012
BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
Chu S et al.
Cancer Research, 2007
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.
Koptyra M et al.
Blood, 2006
Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.
Roumiantsev S et al.
Cancer Cell, 2004
Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl.
Gaston I et al.
Experimental Hematology, 2004
Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Arlinghaus RB
Oncogene, 2002
Critical role for Gab2 in transformation by BCR/ABL.
Sattler M et al.
Cancer Cell, 2002
Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
Hawk N et al.
Cancer Research, 2002
Molecular cloning of Ian4: a BCR/ABL-induced gene that encodes an outer membrane mitochondrial protein with GTP-binding activity.
Dahéron L et al.
Nucleic Acids Research, 2001
Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
Nieborowska-Skorska M et al.
The Journal of Experimental Medicine, 1999
Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant.
Salomoni P et al.
The Journal of Experimental Medicine, 1998
Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase.
Wu Y et al.
Oncogene, 1998
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
Skorski T et al.
The Embo Journal, 1997
Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
Jain SK et al.
Oncogene, 1997
Co-expression with BCR induces activation of the FES tyrosine kinase and phosphorylation of specific N-terminal BCR tyrosine residues.
Li J et al.
The Journal of Biological Chemistry, 1996
The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene.
Senechal K et al.
The Journal of Biological Chemistry, 1996
The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domain.
Maru Y et al.
The Journal of Biological Chemistry, 1996
Inhibition of Bcr serine kinase by tyrosine phosphorylation.
Liu J et al.
Molecular and Cellular Biology, 1996
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Cortez D et al.
Molecular and Cellular Biology, 1995
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
Pendergast AM et al.
Cell, 1993